文献速递淋巴瘤

丹麦人群为基础研究:弥漫大B细胞淋巴瘤患者治疗后缓解且无事件生存24个月后终生损失极小

Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.
PubMed 文献 · J Clin Oncol · 2017-01-17

该丹麦人群为基础研究纳入2003至2011年新诊断的1621例弥漫大B细胞淋巴瘤患者,均接受一线R-CHOP或R-CHOP类方案后达完全缓解或未确认的完全缓解。治疗后5年生存低于匹配一般人群(78% vs 87%),但达到治疗后无事件生存24个月(pEFS24)者超额死亡率降低,<50岁患者生存恢复正常,pEFS24后8年内平均终生损失为0.31月/年。

要点

  • 治疗后5年生存低于匹配一般人群(78% vs 87%,标准化死亡比1.75,P<.001)。
  • 达到pEFS24者超额死亡率降低(标准化死亡比1.27,P<.001)。
  • pEFS24后8年内平均终生损失为0.31月/年(95%CI 0.11至0.50月/年)。

核心结论

  • 该人群为基础研究不支持达到pEFS24的弥漫大B细胞淋巴瘤患者生存完全正常化,但持续缓解2年者残余终生损失估计较低。
  • 作者认为pEFS24是患者咨询中有吸引力且相关的里程碑,并可能作为临床试验的替代终点。

研究设计与样本

  • 丹麦淋巴瘤登记处人群为基础研究,纳入2003至2011年新诊断的弥漫大B细胞淋巴瘤患者共1621例。
  • 所有患者诊断时≥16岁,一线R-CHOP或R-CHOP类方案后达完全缓解或未确认的完全缓解。
  • 将患者生存与匹配的一般人群进行比较。

主要发现

  • 治疗后5年弥漫大B细胞淋巴瘤生存低于匹配一般人群(78%;95%CI 76至80 vs 87%;标准化死亡比1.75;P<.001)。
  • 达到pEFS24者超额死亡率存在但降低(标准化死亡比1.27;P<.001)。
  • 年龄分层分析中,<50岁患者达到pEFS24后生存与一般人群归一(P=.99)。
  • pEFS24后8年内平均终生损失为0.31月/年(95%CI 0.11至0.50月/年)。
  • 将淋巴瘤死亡作为其他原因死亡的竞争事件分析时超额死亡率减弱,提示早期和晚期复发导致弥漫大B细胞淋巴瘤患者死亡率增加。

关键数值与推荐

  • 治疗后5年生存:患者78%(95%CI 76至80)vs 匹配一般人群87%,标准化死亡比1.75,P<.001。
  • 达到pEFS24者标准化死亡比1.27,P<.001。
  • <50岁患者达到pEFS24后与一般人群生存比较P=.99。
  • pEFS24后8年内平均终生损失0.31月/年(95%CI 0.11至0.50月/年)。

临床怎么用

  • 作者认为pEFS24是患者咨询中有吸引力且相关的里程碑。
  • 作者认为pEFS24可能作为临床试验的替代终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were ≥ 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like therapy. Results The 5-year post-treatment DLBCL survival was inferior to survival in the matched general population (78%; 95% CI, 76 to 80; v 87%; standardized mortality ratio, 1.75; P < .001). Excess mortality was present but reduced for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized mortality ratio, 1.27; P < .001). In age-stratified analyses, the survival of patients < 50 years of age was normalized to the general population after achieving pEFS24 ( P = .99). During the first 8 years after pEFS24, the average loss of lifetime was 0.31 mo/y (95% CI, 0.11 to 0.50 mo/y). Excess mortality diminished when analyzing death from lymphoma as competing event to death from other causes, suggesting that early and late relapse is responsible for increased mortality in patients with DLBCL. Conclusion Although this population-based study does not support complete normalization of survival for patients with DLBCL achieving pEFS24, the estimated loss of residual lifetime was low for patients in continuous remission 2 years after ending treatment. Therefore, pEFS24 is an appealing and relevant milestone for patient counseling and could be a surrogate end point in clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jakobsen LH, Bøgsted M, Brown PN, et al. Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. J Clin Oncol. 2017. PMID: 28095160. doi:10.1200/JCO.2016.70.0765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。